SI2516433T1 - Substituirane N-(1 H-indazol-4-il)imidazo(1,2-a)piridin-3-karboksamidne spojine kot cFMS inhibitorji - Google Patents

Substituirane N-(1 H-indazol-4-il)imidazo(1,2-a)piridin-3-karboksamidne spojine kot cFMS inhibitorji

Info

Publication number
SI2516433T1
SI2516433T1 SI201030706T SI201030706T SI2516433T1 SI 2516433 T1 SI2516433 T1 SI 2516433T1 SI 201030706 T SI201030706 T SI 201030706T SI 201030706 T SI201030706 T SI 201030706T SI 2516433 T1 SI2516433 T1 SI 2516433T1
Authority
SI
Slovenia
Prior art keywords
imidazoš1
aćpyridine
indazol
substituted
carboxamide compounds
Prior art date
Application number
SI201030706T
Other languages
English (en)
Slovenian (sl)
Inventor
Mark Laurence Boys
Michael F. Bradley
Robert Kirk Delisle
D. David Hennings
April L. Kennedy
Fredrik P. Marmsater
Matthew David Medina
Mark C. Munson
Bryson Rast
James P. Rizzi
Martha E. Rodriguez
George T. Topalov
Qian Zhao
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of SI2516433T1 publication Critical patent/SI2516433T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201030706T 2009-12-21 2010-12-20 Substituirane N-(1 H-indazol-4-il)imidazo(1,2-a)piridin-3-karboksamidne spojine kot cFMS inhibitorji SI2516433T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28872909P 2009-12-21 2009-12-21
EP10798683.8A EP2516433B1 (en) 2009-12-21 2010-12-20 Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors
PCT/US2010/061341 WO2011079076A1 (en) 2009-12-21 2010-12-20 Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors

Publications (1)

Publication Number Publication Date
SI2516433T1 true SI2516433T1 (sl) 2014-09-30

Family

ID=43568700

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201030706T SI2516433T1 (sl) 2009-12-21 2010-12-20 Substituirane N-(1 H-indazol-4-il)imidazo(1,2-a)piridin-3-karboksamidne spojine kot cFMS inhibitorji

Country Status (31)

Country Link
US (1) US8841455B2 (enExample)
EP (1) EP2516433B1 (enExample)
JP (2) JP5739448B2 (enExample)
KR (1) KR101779630B1 (enExample)
CN (1) CN102822170B (enExample)
AR (1) AR079541A1 (enExample)
AU (1) AU2010333752B2 (enExample)
BR (1) BR112012017123B1 (enExample)
CA (1) CA2785338C (enExample)
CL (1) CL2012001699A1 (enExample)
CO (1) CO6561821A2 (enExample)
CR (1) CR20120389A (enExample)
DK (1) DK2516433T3 (enExample)
ES (1) ES2494590T3 (enExample)
HR (1) HRP20140770T1 (enExample)
IL (1) IL220544A (enExample)
ME (1) ME01894B (enExample)
MX (1) MX2012007329A (enExample)
MY (1) MY163791A (enExample)
NZ (1) NZ601376A (enExample)
PL (1) PL2516433T3 (enExample)
PT (1) PT2516433E (enExample)
RS (1) RS53500B1 (enExample)
RU (1) RU2562977C2 (enExample)
SG (1) SG181861A1 (enExample)
SI (1) SI2516433T1 (enExample)
SM (1) SMT201400142B (enExample)
TW (1) TWI471326B (enExample)
UA (1) UA108222C2 (enExample)
WO (1) WO2011079076A1 (enExample)
ZA (1) ZA201205505B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2464232B1 (en) 2009-08-10 2015-10-07 Samumed, LLC Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
KR101779630B1 (ko) * 2009-12-21 2017-09-18 어레이 바이오파마 인크. ｃＦＭＳ 억제제로서 치환된 Ｎ-（１Ｈ-인다졸-４-일）이미다조［１,２-ａ］피리딘-３-카복사미드 화합물
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
RU2591195C2 (ru) * 2010-12-13 2016-07-10 Эррэй Биофарма Инк. Замещенные n-(1h-индазол-4-ил) имидазол [1,2-а]пиридин-3- карбоксамидные соединения в качестве ингибиторов рецепторной тирозинкиназы iii типа
AU2012308570B2 (en) 2011-09-14 2016-11-10 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CA2872147A1 (en) * 2012-05-02 2013-11-07 Kansas State University Research Foundation Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses
ME03573B (me) 2012-05-04 2020-07-20 Samumed Llc 1H-PIRAZOLO[3,4-B]PIRIDINI l NJIHOVA TERAPEUTSKA UPOTREBA
CN105120862A (zh) 2013-01-08 2015-12-02 萨穆梅德有限公司 Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
KR101756934B1 (ko) 2014-07-08 2017-07-12 연세대학교 산학협력단 피롤로[1,2-a]피라진 유도체, 이의 약학적으로 허용가능한 염, 이들 화합물의 제조방법 및 이를 유효성분으로 함유하는 골다공증 치료 또는 예방용 약학조성물
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
CN204833440U (zh) 2015-07-29 2015-12-02 山东新北洋信息技术股份有限公司 识读组件及纸币清分机
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024015A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
CN108473491A (zh) 2015-11-06 2018-08-31 萨穆梅德有限公司 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
DK3464285T3 (da) 2016-06-01 2022-12-19 Biosplice Therapeutics Inc Fremgangsmåde til fremstilling af n-(5-(3-(7-(3-fluorphenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamid
EP3528808B1 (en) 2016-10-21 2021-10-06 BioSplice Therapeutics, Inc. Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
WO2018083635A2 (en) 2016-11-04 2018-05-11 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
KR102374012B1 (ko) * 2017-05-24 2022-03-14 아비스코 테라퓨틱스 컴퍼니 리미티드 N-(아자릴)시클로락탐-1-카르복사미드 유도체 및 합성법과 그 용법
EP4458810A4 (en) 2021-12-28 2025-12-17 Nippon Shinyaku Co Ltd INDAZOLE COMPOUND AND PHARMACEUTICAL PRODUCT

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952101A (en) 1975-04-14 1976-04-20 Smithkline Corporation α-Amino methyl-5-hydroxy-2-pyridinemethanols
US6723332B2 (en) * 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
CN101146796A (zh) 2005-01-26 2008-03-19 先灵公司 作为蛋白激酶抑制剂用于治疗癌症的3-(吲唑-5-基)-(1,2,4)三嗪衍生物及相关化合物
CA2608733A1 (en) * 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
MX2007015905A (es) 2005-06-24 2008-03-06 Lilly Co Eli Derivados de tetrahidrocarbazol utiles como moduladores de receptor de androgeno (sarm).
JP2009521494A (ja) 2005-12-22 2009-06-04 アルコン リサーチ， リミテッド ｒｈｏキナーゼ媒介性疾患および状態を治療するための（インダゾール−５−イル）−ピラジンおよび（１，３−ジヒドロインドール−２−オン）−ピラジン
WO2008085302A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
NZ580327A (en) * 2007-04-03 2012-02-24 Array Biopharma Inc IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
WO2009071483A1 (en) 2007-12-07 2009-06-11 Via Pharmaceuticals, Inc. 1- (indaz0l-5-yl) -ureas as diacylglycerol acyltransferase inhibitors
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
EP2280705B1 (en) * 2008-06-05 2014-10-08 Glaxo Group Limited Novel compounds
KR101779630B1 (ko) * 2009-12-21 2017-09-18 어레이 바이오파마 인크. ｃＦＭＳ 억제제로서 치환된 Ｎ-（１Ｈ-인다졸-４-일）이미다조［１,２-ａ］피리딘-３-카복사미드 화합물
RU2591195C2 (ru) * 2010-12-13 2016-07-10 Эррэй Биофарма Инк. Замещенные n-(1h-индазол-4-ил) имидазол [1,2-а]пиридин-3- карбоксамидные соединения в качестве ингибиторов рецепторной тирозинкиназы iii типа

Also Published As

Publication number Publication date
WO2011079076A1 (en) 2011-06-30
RU2012131129A (ru) 2014-01-27
AU2010333752A2 (en) 2012-09-06
ES2494590T3 (es) 2014-09-15
US20120258952A1 (en) 2012-10-11
MX2012007329A (es) 2012-10-15
CN102822170B (zh) 2014-12-10
PL2516433T3 (pl) 2014-10-31
TWI471326B (zh) 2015-02-01
ME01894B (me) 2014-12-20
UA108222C2 (xx) 2015-04-10
ZA201205505B (en) 2013-04-24
SG181861A1 (en) 2012-07-30
AU2010333752B2 (en) 2014-12-04
BR112012017123B1 (pt) 2021-07-20
JP5739448B2 (ja) 2015-06-24
CR20120389A (es) 2012-08-16
IL220544A (en) 2016-05-31
CA2785338A1 (en) 2011-06-30
NZ601376A (en) 2014-03-28
PT2516433E (pt) 2014-09-03
SMT201400142B (it) 2014-11-10
KR20120106853A (ko) 2012-09-26
BR112012017123A2 (pt) 2017-10-31
CO6561821A2 (es) 2012-11-15
EP2516433B1 (en) 2014-05-21
CN102822170A (zh) 2012-12-12
JP2015107999A (ja) 2015-06-11
AU2010333752A1 (en) 2012-08-09
CL2012001699A1 (es) 2013-02-01
IL220544A0 (en) 2012-08-30
US8841455B2 (en) 2014-09-23
RS53500B1 (sr) 2015-02-27
AR079541A1 (es) 2012-02-01
DK2516433T3 (da) 2014-08-11
JP2013515070A (ja) 2013-05-02
MY163791A (en) 2017-10-31
CA2785338C (en) 2018-09-18
KR101779630B1 (ko) 2017-09-18
TW201121973A (en) 2011-07-01
RU2562977C2 (ru) 2015-09-10
HK1176928A1 (en) 2013-08-09
EP2516433A1 (en) 2012-10-31
HRP20140770T1 (hr) 2014-11-07

Similar Documents

Publication Publication Date Title
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
DK3419208T3 (da) Fremgangsmåde til diskontinuerlig modtagelsesdrift for long-term-evolution-advanced-bæreraggregering
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
IL207099A0 (en) 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace)
ZA200904138B (en) Substituted spirochromanone derivatives as acc inhibitors
BR112013016154A2 (pt) inibidores de faah
AP2011005913A0 (en) Inhibitors of beta-secretase.
DK3320912T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
EP2376105A4 (en) NKG2D-FC FOR IMMUNOTHERAPY
PL2470546T3 (pl) Związki heksahydrooksazynopterydynowe do zastosowania jako inhibitory MTOR
ZA201100898B (en) Novel inhibitors
EP2763672A4 (en) 1,3-SUBSTITUTED AZETIDINE PDE10 INHIBITORS
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
ZA201007317B (en) Tertiary amine derivatives as phosphodiesterase-4 inhibitors
DK2493312T3 (da) Farmaceutiske faststofsammensætninger, der indeholder en integrase- hæmmer
EP2432400A4 (en) DETECTION ACCESSORIES FOR SURGICAL CLAMPS
EP2313426A4 (en) NEW PROTEASE INHIBITORS
ITPD20090053U1 (it) Paradordi per banchine
ZA201102179B (en) Protease inhibitors
ZA201102837B (en) Phosphodiestarase inhibitors
IT1392058B1 (it) Strumento operatorio, particolarmente per microchirurgia laringea
TWI369343B (en) 4-trimethylammonio-butyrates as cpt2 inhibitors
BRPI0919073A2 (pt) inibidores de protease
IT1400429B1 (it) Utensile per diaframmi sottili.
GB0816125D0 (en) Novel inhibitors